This announcement is a separate document:
艾迪药业董事会关于公司本次重大资产重组符合《上市公司监管指引第9号—上市公司筹划和实施重大资产重组的监管要求》第四条规定的说明
The board of directors of Jiangsu Aidea Pharmaceutical has provided an explanation regarding the company's major assets restructuring, which is in compliance with the regulatory requirements of Article 4 of the Guidelines for the Supervision of Listed Companies No. 9 - the Regulations on Planning and Implementation of Major Asset Restructurings by Listed Companies.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.